Keywords: Biosimilars, Merck KGaA, Dr Reddy's, Co-development, Manufacturing, Commercialization, Merck Serono, MAbs

Merck KGaA collaborates with Dr Reddy's on biosimilars

Article | 07 June 2012

Print This

With the aim of capitalizing on the batch of patent expires for blockbuster biotechnology-based drugs (worth some 40% of global biologics ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in